长春高新：子公司GenSci142胶囊国内临床试验申请获批

Core Viewpoint - Changchun High-tech announced that its subsidiary, Gensci Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial of GenSci142 capsules, aimed at treating bacterial vaginosis. This marks the first new drug clinical trial application approved under the "30-day channel" for innovative drug review and approval [1] Group 1 - The GenSci142 capsule is classified as a Class 1 innovative biological product [1] - The capsule has advantages such as rapid onset of action and remains effective against metronidazole-resistant infections [1] - Successful progress in clinical trials could help the company optimize its business and product structure [1] Group 2 - There is uncertainty regarding the clinical trial process [1]